Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, has announced the publication of preclinical research supporting its engineered suppressor tRNA platform for Duchenne muscular dystrophy (DMD). The study, conducted by scientists at Tevard, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research, appears in Science Advances. The paper, titled “Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy,” is available at https://doi.org/10.1126/sciadv.aeg3466.
DMD is a severe, progressive muscle-wasting disease caused by mutations in the dystrophin gene. Approximately 10-15% of DMD cases result from nonsense mutations, which introduce premature stop codons that halt dystrophin production. Current treatments for DMD are limited and none cure the disease. The new research describes an engineered suppressor tRNA gene therapy designed to overcome these mutations by enabling the cellular machinery to read through premature stop codons and produce full-length, functional dystrophin.
In a preclinical DMD model, the engineered suppressor tRNA therapy restored physiological levels of full-length dystrophin, improved muscle strength and motor coordination, and was well tolerated. Importantly, the engineered tRNAs targeted disease-causing nonsense mutations while leaving normal stop codons intact, demonstrating exquisite selectivity. This selectivity is critical because indiscriminate readthrough of normal stop codons could lead to harmful off-target effects. The ability to specifically target premature termination codons without affecting normal protein synthesis sets this approach apart from other mutation-agnostic therapies.
The implications of this research extend beyond DMD. Because the platform targets nonsense mutations as a class, it has potential applications for other muscular dystrophies and a broad range of genetic diseases caused by premature stop codons. Tevard Biosciences is advancing a pipeline of programs that includes Duchenne muscular dystrophy, genetic cardiomyopathies, and neurological disorders such as epilepsies. The company’s proprietary suppressor tRNA platform is designed to restore endogenous, full-length protein expression for diseases caused by premature termination codons.
“This publication represents a significant step forward for Tevard’s suppressor tRNA platform and its potential to treat DMD,” said a representative of Tevard Biosciences. “By restoring full-length dystrophin in a preclinical model, we have demonstrated that our approach could address the root cause of the disease for patients with nonsense mutations.”
The study’s findings underscore the therapeutic potential of engineered suppressor tRNAs as a versatile gene therapy strategy. Unlike exon-skipping approaches that produce truncated dystrophin, this platform aims to restore full-length protein, which may offer greater functional benefit. The positive preclinical results support further development and eventual clinical testing. For more information about Tevard Biosciences and its pipeline, visit Tevard.com.
